News
-
Acquired NET(New Excellent Technology)
HAMA-PA, a “Medical-grade photocrosslinkable
hyaluronic acid” developed by bio venture SNVIA Co., Ltd. (CEO K.Lee),
has received government certification as a New Excellent Technol
2026.03.10
-
SNVIA Develops Microneedle Patch for Malaria
In remote regions of Africa, where
malaria cases are most prevalent, refrigeration facilities and medical
personnel are often scarce. Even when vaccines are available, the lack of
2026.03.10
-
SNVIA Advances Microneedle Drug Delivery
SNVIA is a venture company founded in
2016 after acquiring microneedle technology developed by a team from the
Department of Biomaterials Science at Pusan National University. Micr
2026.03.10
-
SNVIA Develops Light-Based Wound Closure Device
Korean bio venture SNVIA Co., Ltd. has
partnered with Pusan National University Technology Holdings and Japanese
pharmaceutical company Japan Bio Products (JBP) to jointly de
2026.03.10
-
PNU Develops Lu-177 Microsphere Cancer Therapy
Pusan National University and Pusan
National University Hospital announced on December 5 that they will receive a
supply of Lutetium-177 (Lu-177) from the Korea Atomic Energy
2026.03.10
-
SNVIA Signs MOU with K-MEDI hub for R&D
The Pharmaceutical Production Center of
K-MEDI hub (Daegu-Gyeongbuk
Medical Innovation Foundation) has signed a memorandum of understanding (MOU)
with SNVIA Co., Ltd. to sup
2026.03.10
-
PNU Develops Light-Sealing Technology for Surgery
A research team at Pusan National
University is rewriting the history of surgical tissue closure with an advanced
medical photocrosslinking
material technology. The team has devel
2026.03.10
-
SNVIA Partners with JBP for Medical Devices
Located in Busan company SNVIA Co., Ltd.
is accelerating commercialization and product development efforts by partnering
with a Japanese firm to leverage photo-crosslinking technol
2026.03.10
-
SNVIA Invests in Miryang Nano Industrial Complex
Miryang City has signed a KRW 39.1
billion investment agreement aimed at boosting regional industrial growth.
Under the agreement, SNVIA Co., Ltd. will
invest KRW 5 billion to b
2026.03.10
-
Microneedle Patches Enable Painless Drug Delivery
Microneedles are produced by
manufacturing large quantities of ultra-fine plastic needles and coating them
with medication. The needles are densely arranged on a patch, which is th
2026.03.10
